Recently, K-Ras mutations detected by allelic discrimination on tumour DNA, have been demonstrated to be an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab (Lièvre et al, 2008). This evidence concerns the gene KRAS and colorectal cancer.